MEI Pharma (NASDAQ:MEIP) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of MEI Pharma (NASDAQ:MEIP) in a report released on Saturday morning. The firm issued a buy rating on the stock.

MEI Pharma Price Performance

Shares of MEI Pharma stock opened at $2.87 on Friday. MEI Pharma has a 1-year low of $2.30 and a 1-year high of $5.06. The business’s fifty day moving average price is $2.70 and its two-hundred day moving average price is $2.92. The company has a market capitalization of $19.11 million, a P/E ratio of -0.41 and a beta of 0.78.

MEI Pharma (NASDAQ:MEIP) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.20) earnings per share for the quarter. On average, research analysts expect that MEI Pharma will post -5.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MEI Pharma

An institutional investor recently bought a new position in MEI Pharma stock. World Investment Advisors LLC acquired a new position in MEI Pharma, Inc. (NASDAQ:MEIP) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 25,000 shares of the company’s stock, valued at approximately $71,000. World Investment Advisors LLC owned approximately 0.38% of MEI Pharma as of its most recent filing with the SEC. Institutional investors and hedge funds own 52.38% of the company’s stock.

About MEI Pharma

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.